Rabbit Recombinant Monoclonal VEGF Receptor 3 antibody. Carrier free. Suitable for WB and reacts with Human samples.
pH: 7.2 - 7.4
Constituents: PBS
IP | Flow Cyt | WB | IHC-P | ICC/IF | |
---|---|---|---|---|---|
Human | Not recommended | Not recommended | Tested | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info - | Notes - |
Select an associated product type
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced production of VEGFC, and to a lesser degree VEGFA, thereby creating a positive feedback loop that enhances FLT4 signaling. Modulates KDR signaling by forming heterodimers. The secreted isoform 3 may function as a decoy receptor for VEGFC and/or VEGFD and play an important role as a negative regulator of VEGFC-mediated lymphangiogenesis and angiogenesis. Binding of vascular growth factors to isoform 1 or isoform 2 leads to the activation of several signaling cascades; isoform 2 seems to be less efficient in signal transduction, because it has a truncated C-terminus and therefore lacks several phosphorylation sites. Mediates activation of the MAPK1/ERK2, MAPK3/ERK1 signaling pathway, of MAPK8 and the JUN signaling pathway, and of the AKT1 signaling pathway. Phosphorylates SHC1. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Promotes phosphorylation of MAPK8 at 'Thr-183' and 'Tyr-185', and of AKT1 at 'Ser-473'.
VEGFR3, FLT4, Vascular endothelial growth factor receptor 3, VEGFR-3, Fms-like tyrosine kinase 4, Tyrosine-protein kinase receptor FLT4, FLT-4
Rabbit Recombinant Monoclonal VEGF Receptor 3 antibody. Carrier free. Suitable for WB and reacts with Human samples.
pH: 7.2 - 7.4
Constituents: PBS
ab243565 is the carrier-free version of Anti-VEGF Receptor 3 antibody [EPR22293-14] ab243232.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
VEGF Receptor 3 also known as FLT-4 is a protein essential for lymphatic development and is expressed mainly in lymphatic endothelial cells. This receptor has a molecular mass of approximately 195 kDa. VEGF Receptor 3 belongs to the tyrosine kinase family and binds with high affinity to its ligands VEGF-C and VEGF-D. These interactions lead to the activation of intracellular signaling cascades that promote cell proliferation migration and survival.
The VEGF Receptor 3 acts as an important regulator of lymphangiogenesis which is the growth of new lymphatic vessels from pre-existing ones. It is not typically part of larger protein complexes but it works closely with its ligands to facilitate the processes associated with lymph vessel formation and function. Proper activity of VEGF Receptor 3 is necessary for maintaining normal lymphatic vessel remodeling and function during development and in some adult tissues.
The receptor is involved in the VEGF signaling pathway which plays an important role in vascular and lymphatic development. This pathway intersects with others like the PI3K/AKT pathway a critical mediator of cell growth and survival. VEGF Receptor 3 interacts with related receptors such as VEGF Receptor 2 in these pathways to regulate complex and essential physiological processes.
VEGF Receptor 3 has been linked to lymphedema which is swelling due to lymphatic system dysfunction and certain cancers where excessive angiogenesis occurs. Mutations or dysregulations in the receptor's signaling can lead to these conditions. In cancer for instance VEGF Receptor 3 along with its associated protein VEGF-C can promote tumor lymphangiogenesis facilitating metastasis. Antagonists like anti-VEGF therapies target these receptors to inhibit tumor progression and manage these disorders.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Blocking/Diluting buffer and concentration: 5% NFDM/TBST
This blot was developed using a higher sensitivity ECL substrate.
The molecular weight observed is consistent with the literatures (PMID: 18538738, PMID: 7692369, PMID: 14648657).
Negative control: MCF7 (PMID: 18538738).
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-VEGF Receptor 3 antibody [EPR22293-14] ab243232).
All lanes: Western blot - Anti-VEGF Receptor 3 antibody [EPR22293-14] (Anti-VEGF Receptor 3 antibody [EPR22293-14] ab243232) at 1/1000 dilution
Lane 1: HEL (human erythroleukemia erythroblast cell line) whole cell lysate at 20 µg
Lane 2: MCF7 (human breast adenocarcinoma cell line) whole cell lysate at 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Predicted band size: 146 kDa
Observed band size: 125 kDa, 175 kDa, 80 kDa
Exposure time: 3min
This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (Anti-VEGF Receptor 3 antibody [EPR22293-14] ab243232).
Anti-FLT4 antibody [EPR22293-14] (Anti-VEGF Receptor 3 antibody [EPR22293-14] ab243232) staining at 1/1000 dilution, shown in green; Mouse anti-CANX [CANX/1543] (Anti-Calnexin antibody [CANX/1543] ab238078) loading control staining at 1/20000 dilution, shown in red. In Western blot, Anti-VEGF Receptor 3 antibody [EPR22293-14] ab243232 was shown to bind specifically to FLT4. First, unboiled samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution.
All lanes: Western blot - Anti-VEGF Receptor 3 antibody [EPR22293-14] (Anti-VEGF Receptor 3 antibody [EPR22293-14] ab243232) at 1/1000 dilution
Lane 1: HEL 92.1.7 cell lysate at 20 µg
Lane 2: MCF7 cell lysate at 20 µg
All lanes: Goat anti-Rabbit IgG H&L 800CW and Goat anti-Mouse IgG H&L 680RD at 1/20000 dilution
Performed under reducing conditions.
Predicted band size: 146 kDa
Observed band size: 200 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com